Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25.

PMID:
19926282
2.

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors.

Hammond M, Washburn DG, Hoang HT, Manns S, Frazee JS, Nakamura H, Patterson JR, Trizna W, Wu C, Azzarano LM, Nagilla R, Nord M, Trejo R, Head MS, Zhao B, Smallwood AM, Hightower K, Laping NJ, Schnackenberg CG, Thompson SK.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4441-5. doi: 10.1016/j.bmcl.2009.05.051. Epub 2009 May 18.

PMID:
19497745
3.

Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor.

McCleland BW, Davis RS, Palovich MR, Widdowson KL, Werner ML, Burman M, Foley JJ, Schmidt DB, Sarau HM, Rogers M, Salyers KL, Gorycki PD, Roethke TJ, Stelman GJ, Azzarano LM, Ward KW, Busch-Petersen J.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. Epub 2006 Dec 23.

PMID:
17236763
7.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR.

Drug Metab Dispos. 2004 Feb;32(2):172-7.

PMID:
14744938
8.

Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.

Miller WH, Manley PJ, Cousins RD, Erhard KF, Heerding DA, Kwon C, Ross ST, Samanen JM, Takata DT, Uzinskas IN, Yuan CC, Haltiwanger RC, Gress CJ, Lark MW, Hwang SM, James IE, Rieman DJ, Willette RN, Yue TL, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1483-6.

PMID:
12668017
9.

Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens.

Perng CY, Kearney AS, Palepu NR, Smith BR, Azzarano LM.

Int J Pharm. 2003 Jan 2;250(1):147-56.

PMID:
12480281
10.

Pharmacokinetics of SB-247083, a potent and selective endothelin(A) receptor antagonist, in the rat, dog, and monkey.

Ward KW, Azzarano LM, Morgan JA, Gould MJ, Perng CY, Souder PR, Lundberg D, Smith BR.

Biopharm Drug Dispos. 2002 Nov;23(8):339-49.

PMID:
12415574
11.

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics.

Ward KW, Proksch JW, Salyers KL, Azzarano LM, Morgan JA, Roethke TJ, McSurdy-Freed JE, Levy MA, Smith BR.

Xenobiotica. 2002 Mar;32(3):221-33.

PMID:
11958561
12.

SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR.

Pharm Res. 2001 Sep;18(9):1336-44.

PMID:
11683250
13.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

J Med Chem. 2000 Jan 13;43(1):22-6. No abstract available.

PMID:
10633035
14.

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, Mumaw JA, Newlander KA, Pirhalla JL, Roethke TJ, Salyers KL, Souder PR, Stelman GJ, Smith BR.

Drug Metab Dispos. 1999 Nov;27(11):1232-41.

PMID:
10534306
15.

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.

PMID:
10406646

Supplemental Content

Loading ...
Support Center